The FDA on Tuesday granted Merck priority review for its investigational pneumococcal vaccine, making strides ahead of Pfizer in the companies’ yearslong contest atop the market for the vaccines.
The priority review was awarded for Merck’s V116, a 21-valent vaccine to prevent pneumococcal disease and pneumococcal pneumonia in adults. The FDA is planning to make a decision on approval by June 2024.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.